Special Issue

Advances in Epitope-Based Vaccine Design

Message from the Guest Editors

The design of epitope-driven or peptide-based vaccines is attractive. They are easier to produce and construct, they lack any infectious potential, and offer chemical stability. Moreover, for proper engagement of cellular and humoral immunity, a combining task for different peptides is more appreciated. The construction of multi-epitope vaccines by linking the safest and B-cell derived T-cell antigenic epitope offers many significant benefits. These include broader intrinsic immunogenicity, both humoral and cellular immunity can properly be engaged and improve T-cell epitopes population coverage. The novel combination of immuno-informative approaches, together with the knowledge of host immune responses and the exponential increase in complete genome sequencing of pathogen strains, now makes it possible to select the most antigenic epitopes. This Special Issue aims to detail the advancemes in the epitope-based vaccines development. The Special Issue covers said vaccine development both on computational and experimetnal techniques for variety of pathogens as well as cancer diseases. In this Special Issue, original research articles and reviews are welcome.

Guest Editors

Dr. Sajjad Ahmad

Dr. Muhammad Khurram

Dr. Sumra Wajid Abbasi

Deadline for manuscript submissions

closed (31 May 2023)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/135742

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI